Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B

References

• Dembek ZF, Smith LA, Rusnak JM. 2007. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 1:122–134. doi:10.1097/DMP.0b013e318158c5fd.
   PubMed Web of Science ®Google Scholar
• Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. 27;2007:303–318.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol Rev. 80:717–766. doi:10.1152/physrev.2000.80.2.717.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, et al. 2010. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol. 137:271–280. doi:10.1016/j.clim.2010.07.005.
   PubMed Web of Science ®Google Scholar
• Shukla HD, Sharma SK. 2005. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 31:11–18. doi:10.1080/10408410590912952.
   PubMed Web of Science ®Google Scholar
• Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 27:552–558.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Eswaramoorthy S. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 7:693–699.
   PubMedGoogle Scholar
• Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. 1992. Botulinum neurotoxins are zinc proteins. J Biol Chem. 267:23479–23483.
   PubMed Web of Science ®Google Scholar
• Gu S, Jin R. 2013. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol. 364:21–44. doi:10.1007/978-3-642-33570-9_2.
   PubMed Web of Science ®Google Scholar
• Lee K, Gu S, Jin L, Le TTN, Cheng LW, Strotmeier J, Kruel AM, Yao G, Perry K, Rummel A, et al. 2013. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. Plos Pathogens. 9:e1003690. doi:10.1371/journal.ppat.1003690.
   PubMed Web of Science ®Google Scholar
• Matak I, Lackovic Z. 2014. Botulinum toxin A, brain and pain. Prog Neurobiol. 119-120:39–59. doi:10.1016/j.pneurobio.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Inglesby TV, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. 2001. Botulinum toxin as a biological weapon: medical and public health management. Jama. 285:1059–1070.
   PubMed Web of Science ®Google Scholar
• Karalewitz AP, Barbieri JT. 2012. Vaccines against botulism. Curr Opin Microbiol. 15:317–324. doi:10.1016/j.mib.2012.05.009.
   PubMed Web of Science ®Google Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009;27(Suppl 4):D33–9. doi:10.1016/j.vaccine.2009.08.059.
   PubMed Web of Science ®Google Scholar
• Atassi MZ. 2004. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 19:S68–S84. doi:10.1002/mds.20020.
   PubMed Web of Science ®Google Scholar
• Moreira GM, Cunha CE, Salvarani FM, Goncalves LA, Pires PS, Conceicao FR, Lobato FCF. 2014. Production of recombinant botulism antigens: a review of expression systems. Anaerobe. 28:130–136. doi:10.1016/j.anaerobe.2014.06.003.
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith TJ, Montgomery VA, Smith LA. 1998. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun. 66:4817–4822.
   PubMed Web of Science ®Google Scholar
• Gurkan C, Ellar DJ. 2005. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact. 4:1–8. doi:10.1186/1475-2859-4-1.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW. 2008. Evaluation of a recombinant Hc of clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol Cvi. 15:1819. doi:10.1128/CVI.00239-08.
   PubMed Web of Science ®Google Scholar
• Holley JL, Elmore M, Mauchline M, Minton N, Titball RW. 2000. Cloning, expression and evaluation of a recombinant sub-unit vaccine against clostridium botulinum type F toxin. Vaccine. 19:288–297.
   PubMed Web of Science ®Google Scholar
• Liu B, Shi D, Chang S, Gong X, Yu Y, Sun Z, Wu J. 2015. Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast. Sci Rep. 5:7678. doi:10.1038/srep07678.
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith LA. 2000. Development of vaccines for prevention of botulism. Biochimie. 82:955–966.
   PubMed Web of Science ®Google Scholar
• Gao YL, Gao S, Kang L, Nie C, Wang JL. 2010. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Hum Vaccin. 6:462–466.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Singh BR. 2004. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif. 34:8–16. doi:10.1016/j.pep.2003.10.015.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Na L, Zhu HQ, Wang RL, Yun D, Shuang W, Yu WY, Sun ZW. 2009. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine. 27:2816–2822. doi:10.1016/j.vaccine.2009.02.091.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Gong ZW, Ma Y, Zhang SM, Zhu HQ, Wang WB, Du Y, Wang S, Yu WY, Sun ZW. 2011. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate. Vaccine. 29:5978–5985. doi:10.1016/j.vaccine.2011.06.039.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Shi DY, Liu S, Gong ZW, Wang S, Sun ZW. 2015. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Hum Vaccin. 11:468–473. doi:10.4161/hv.29714.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Wang WB, Li N, Wang S, Yu WY, Sun ZW. 2010. Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate. Biologicals. 38:658–663. doi:10.1016/j.biologicals.2010.08.001.
   PubMed Web of Science ®Google Scholar